« Back to Record
Kelley, R. K., Rimassa, L., Cheng, A. L., Kaseb, A., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., Verset, G., Gane, E., Borbath, I., Rangel, J. D. G., Ryoo, B. Y., Makharadze, T., Merle, P., Benzaghou, F., Banerjee, K., Hazra, S., Fawcett, J., & Yau, T. (2022). Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet oncology, 23(8), 995-1008. doi:10.1016/S1470-2045(22)00326-6
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/346794



